Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab in platinum-resistant ovarian cancer
NCT00516841Phase 2Terminated
- Sponsor
- Facet Biotech Corporation
- Start
- Aug 2007
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of volociximab in ovarian cancer, primary peritoneal cancer (PPC), sponsored by Facet Biotech Corporation. Started Aug 2007; status: terminated.
02
Drugs
volociximab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00516841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516841.